Tumor News and Research

RSS

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

New findings disclose mechanisms that control Rb2/p130 gene expression in lung cancer cells

Despite innumerable studies on lung cancer, many aspects of the disease have yet to be understood, including the role played by the retinoblastoma-related protein Rb2/p130 in the evolution of the disease.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology

Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that results from a Phase II study of Lymphoseek® (Tilmanocept) have been published online in the Annals of Surgical Oncology and demonstrate the tracing agent's ability to identify tumor-draining lymph nodes in breast cancer and melanoma patients.

25 Feb 2011

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

25 Feb 2011

Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients

Researchers say a new kind of tracing agent is more accurate than current methods in helping identify tumor-draining sentinel lymph nodes in breast cancer and melanoma patients. That's the finding in a new study that appears in the online version of the Annals of Surgical Oncology.

25 Feb 2011

Simpler method of making water-soluble short protein chains with spiral structures

Researchers have developed a simple method of making short protein chains with spiral structures that can also dissolve in water, two desirable traits not often found together. Such structures could have applications as building blocks for self-assembling nanostructures and as agents for drug and gene delivery.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

25 Feb 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

BRI and Eureka Genomics form strategic alliance to advance cancer treatments

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and bioinformatics pioneer Eureka Genomics (EG) have formed a strategic alliance to achieve a better understanding of the causes of colorectal cancer, potentially leading to advancements in the disease's prevention, management and treatment.

24 Feb 2011

Nonsurgical methods to identify critical lymph nodes in patients with breast cancer

Researchers at the University of California, San Diego are developing nonsurgical methods for identifying critical lymph nodes to help doctors determine courses of treatment for breast cancer patients.

24 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

Cannabis Science extract treatments help kill cancer cells

Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells.

23 Feb 2011

ETH scientists warn about impact of cell phone radiation in brain of healthy adults

Expert scientists working with Environmental Health Trust, a nonprofit research and educational group, say that new studies showing that cell phone radiation excites the brain strengthen the need for a major research program on cell phones and health, revamping approaches to setting standards, and putting warnings on cell phones.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Tumor News and Research

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

p53 gene blocks EMT essential to cancer metastasis

New findings disclose mechanisms that control Rb2/p130 gene expression in lung cancer cells

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology

New study discloses mechanism controlling Rb2/p130 gene expression in lung cancer cells

Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients

Simpler method of making water-soluble short protein chains with spiral structures

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

BRI and Eureka Genomics form strategic alliance to advance cancer treatments

Nonsurgical methods to identify critical lymph nodes in patients with breast cancer

EpiCept 2010 fourth quarter net loss is $0.06 per share

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Cannabis Science extract treatments help kill cancer cells

ETH scientists warn about impact of cell phone radiation in brain of healthy adults

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News